Slide 1: Third Quarter 2023 Financial Results and Corporate Update
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities
Slide 3: Agenda
Agenda Third Quarter 2023 Financial Results and Corporate Update 02 | Third Quarter 2023 and Subsequent Highlights 04 | Q&A Session Financial and Operating Results Summary and Highlights 03 | Anticipated Clinical Milestones 3 | © immunic, inc. | Nov/14/2023 & Immunic
Slide 4: Third Quarter 2023 and Subsequent Highlights
Slide 5: August: Enrolled Last Patient in Phase 2 CALLIPER Trial
August: Enrolled Last, 467" Patient in Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial* Screening Period Muximunicio0 weeks = Coot Investigator: Robert J. Fox, M.D., Cleveland Clini = 467 patient
Slide 6: October: Reported Positive Interim Data from Phase 2 CALLIPER Trial
October: Reported Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Improvements in Serum Nfl for Vidofludimus Calcium Consistent Throughout the Overall PMS Population and All Subtypes Change to Week 24 as Compared to Placebo in % of Baseline
Slide 7: NfL Reduction Compares Favorably with Other MS Therapies
NfL Reduction Compares Favorably with Other MS Therapies CALLIPER Interim Data Compared to Select Historical Trials Vidofludimus Ocrelizumab Vidofludimus Siponimod _Vidofludimus _Siponimod Vidofludimus Ocrelizumab — Evobrutinib PPMS PPMS n-aSPMS n-aSPMS aSPMS aSPMS RRMS RMS RRMS (CALLIPER) (ORATORIO
Slide 8: October: Presented Phase 2 EMPhASIS Trial Data at MSMilan2023
October: Presented Phase 2 EMPhASIS Trial Data of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023 = MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting = October 11-13 in Milan, Italy = Virtual e-poster: Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple
Slide 9: November: Received Notice of Allowance for United States Patent
November: Received Notice of Allowance for United States Patent Protecting the Treatment of RMS with Vidofludimus and Its Salts Immunic has created a multilayered approach to exclusivity for vidofludimus calcium: Patent on composition-of-matter for salt forms of vidofludimus calcium, granted in the
Slide 10: July: Hosted Virtual Celiac Disease Roundtable
Gimmie July: Hosted Virtual Celiac Disease Roundtable ‘Ongoing Active Celiac Disease and Its High Unmet Medical Need for New Treatment Options Immunic’s Virtual Celiac Disease KOL Roundtable ‘Thursday, July 20, 2023, 8:00 - 9:00 am Eastern Time Ongoing Active Celiac Disease and Its High Unmet Ee ORE
Slide 11: October: Presented Two Abstracts at UEG Week 2023
October: Presented Two Abstracts at the UEG (United European Gastroenterology) Week 2023 (October 14-17 in Copenhagen, Denmark) = Positive Phase 1b Data of IMU-856 in Celiac Disease Positive Phase 2 Maintenance Phase Data of Vidofludimus Calcium in UC = Moderated Poster: Franziska Burianek, M.D., =
Slide 12: November: Presented Phase 1b Data of IMU-856 at AOECS 2023
November: Presented Phase 1b Data of IMU-856 in Celiac Disease at the AOECS 35th General Assembly Conference 2023 “ & Immunic AOECS 12 | © immunic, inc. | Nov/14/2023 | ema: = Association of European Coeliac Societies (AOECS) 35th General Assembly Conference 2023 = November 2-5 in Athens, Greece = V
Slide 13: Financial and Operating Results Summary and Highlights
Slide 14: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months Nine Months Ended September 30, Ended September 30, 2023 2022 2023 2022 Operating expenses: Research and development $_19,796| $ 16,537| $63,931] $50,520] General and administra
Slide 15: Anticipated Clinical Milestones
Slide 16: Several Clinical Value Inflection Points Ahead
Several Clinical Value Inflection Points Ahead IMU-838 Readout phase 2 CALLIPER trial in PMS estimated for April of 2025 Interim futility analysis phase 3 ENSURE IMU-838 program estimated for late 2024 in RMS Readout of first phase 3 ENSURE trial estimated for end of 2025 Phase 2 clinical trial in p
Slide 17: Q&A Session
Slide 18: Slide 18
Slide 19: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Key Milestones = Interim futility analysis of ENSURE program in RMS planned after approximately half of the events a occurred, estimated for late 2024 Vidoflu
Slide 20: Thank You!
Thank You! Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grifelfing (Munich) Germany Jessica Breu Head of IR & Communications & Phone: +49-89-2080477-09 & Email: ir@imux.com ® Web: www.imux.com Immunic Australia Pty. Ltd. Melbourne Austral